Blood cancers

Longer term data builds on new agents for polycythaemia vera

Ruxolitinib is a safe and effective long-term treatment option for patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea, research shows.  A five-year follow-up of the RESPONSE trial, which randomised 342 patients to either the JAK 1 and 2 inhibitor or best available therapy, confirmed the initial primary response to ruxolitinib was ...

Already a member?

Login to keep reading.

© 2021 the limbic